Meeting
2022 ASCO Genitourinary Cancers Symposium
Final analysis of a non-interventional study on cabozantinib in patients with advanced renal cell carcinoma after prior checkpoint inhibitor therapy (CaboCHECK).
Authors
Viktor Grünwald
Universitätsklinikum Essen (AöR), Westdeutsches Tumorzentrum Essen, Innere Klinik (Tumorforschung), Essen, Germany
Viktor Grünwald , Martin Boegemann , Mohammad-Reza Rafiyan , Guenter Niegisch , Marco Julius Schnabel , Anne Flörcken , Michael Maasberg , Christoph Maintz , Mark-Oliver Zahn , Anke Wortmann , Andreas Hinkel , Jochen Casper , Christopher Darr , Thomas Hilser , Matthias Schulze , Disorn Sookthai , Caroline Schoenherr , Philipp Ivanyi
Organizations
Universitätsklinikum Essen (AöR), Westdeutsches Tumorzentrum Essen, Innere Klinik (Tumorforschung), Essen, Germany, Universitätsklinikum Münster, Westdeutsches Tumorzentrum Münster, Klinik für Urologie und Kinderurologie, Münster, Germany, Krankenhaus Nordwest gGmbH, Institut für Klinisch-Onkologische Forschung (IKF), Frankfurt, Germany, Universitätsklinikum Düsseldorf, Klinik für Urologie, Konservative Urologische Onkologie, Düsseldorf, Germany, Klinik für Urologie der Universität Regensburg am Caritas-Krankenhaus St. Josef, Regensburg, Germany, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany, Institut für Versorgungsforschung, Mayen, Germany, MVZ West GmbH Würselen, Wuerselen, Germany, MVZ Onkologische Kooperation Harz, Goslar, Germany, Onkologiezentrum Soest-Iserlohn, Medizinisches Versorgungszentrum GbR, Soest-Paradiese, Germany, Franziskus Hospital Bielefeld, Onkologisches Zentrum, Bielefeld, Germany, Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Onkologie und Hämatologie, Oldenburg, Germany, Universitätsklinikum Essen Klinik für Urologie, Essen, Germany, Praxis Dr. Schulze, Markkleeberg, Germany, Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt, Germany, Medizinisch Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany
Research Funding
Pharmaceutical/Biotech Company
Background: Data for cabozantinib after IO-combinations in metastatic renal cell carcinoma (mRCC) remain scarce. We therefore evaluated safety and effectiveness of cabozantinib after failure of IO-based therapies. Methods: Data from patients (pts) with mRCC and cabozantinib treatment after IO-based therapy was retrospectively collected from medical records. Primary endpoint was the incidence of serious adverse events (SAEs). Response rate was assessed clinically (CRR) and/or according to RECIST 1.1. Overall Survival (OS) and Progression Free Survival (PFS) were assessed from start of therapy and data were compared for pts with starting dose of 60 mg (cohort A) vs < 60 mg (cohort B) in a post-hoc analysis. Descriptive statistics and KM-plots were utilized, where appropriate. Results: This final analysis (cut off 08-Oct-21) assessed 56 eligible pts (71.4% male) with median age of 66 yrs. 87.5% (n = 49) had previous nephrectomy. 66.1% (n = 37) had clear cell RCC. 89.3% (n = 50) had ≥2 previous lines. ECOG ≤1 was 33.9% (n = 19). IMDC factors were 0 in 2 (3.6%), ≥1 in 21 (37.5%), missing in 31 pts (55.4%). 62.5% (n = 35) started at reduced dose. 55.4% (n = 31) required dose reductions and 1.8% (n = 1) discontinuation. Median treatment duration was 6.1 months (m). PR was 10.7% (n = 6), SD 19.6% (n = 11), PD 12.5% (n = 7) and missing in 57.1% (n = 32). Median OS and PFS were 15.34 m (95% CI 8.94, 20.93) and 6.34 m (95% CI 5.29, 8.25) in the ITT, 10.48 m (95% CI 6.01, 34.14) and 6.51 m (95% CI 2.99, 10.87) in cohort A and 16.46 m (95% CI 9.56, 23.33) and 6.34 m (95% CI 4.86, 8.71) in cohort B, respectively. All grade AEs and grade 3-5 AEs were 87.5% (n = 49) and 44.6% (n = 25) in the ITT, 95.0% (n = 19) and 55.0% (n = 11) in cohort A and 85.7% (n = 30) and 40.0% (n = 14) in cohort B. SAEs were reported in 21.4% (n = 12) of pts, which were 30.0% (n = 6) of cohort A and 17.1% (n = 6) of cohort B. Treatment related SAEs were reported in 10.7% (n = 6) of pts, which were 15.0% (n = 3) in cohort A and 8.6% (n = 3) in cohort B. Conclusions: Cabozantinib directly after IO therapy was safe and feasible. No new safety signals were reported. A reduced starting dose was frequently utilized and was not associated with adverse outcomes. Our data supports the use of cabozantinib after IO-failure. Major limitation was the retrospective nature of our study.
| Cohort A, n = 20 | Cohort B, n = 35 | Total N = 56* | |
|---|---|---|---|
| AE, % | 95.0 (n = 19) | 85.7 (n = 30) | 87.5 (n = 49) |
| SAE, % | 30.0 (n = 6) | 17.1 (n = 6) | 21.4 (n = 12) |
| Treatment related SAE, % | 15.0 (n = 3) | 8.6 (n = 3) | 10.7 (n = 6) |
| PFS, mo (95%CI) | 6.51 (2.99-10.87) | 6.34 (4.86-8.71) | 6.34 (5.29-8.25) |
| OS, mo (95%CI) | 10.48 (6.01-34.14) | 16.46 (9.56-23.33) | 15.34 (8.94-20.93) |
| PR, % | 10.0 (n = 2) | 11.4 (n = 4) | 10.7 (n = 6) |
| SD, % | 15.0 (n = 3) | 22.9 (n = 8) | 19.6 (n = 11) |
| PD, % | 20.0 (n = 4) | 8.6 (n = 3) | 12.5 (n = 7) |
| Missing, % | 55.0 (n = 11) | 57.1 (n = 20) | 57.1 (n = 32) |
*1 pts. with missing values.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04147143
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 357)
DOI
10.1200/JCO.2022.40.6_suppl.357
Abstract #
357
Poster Bd #
Online Only
Abstract Disclosures
Similar Abstracts
Abstract
2024 ASCO Genitourinary Cancers Symposium
Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.
First Author: Renee Maria Saliby
Abstract
2024 ASCO Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy (CN) in the immune checkpoint inhibitor (ICI) era of metastatic renal cell carcinoma (mRCC): A systematic review and individual patient data (IPD) meta-analysis of 2319 patients.
First Author: Dimitrios Makrakis
Abstract
2023 ASCO Genitourinary Cancers Symposium
Safety and tolerability of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study).
First Author: Annalisa Guida
Abstract
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif